• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对一名患有3型血管性血友病且反复出现胃肠道出血的患者,使用中间纯度的凝血因子VIII浓缩物(海莫莱士)进行长期预防治疗。

Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding.

作者信息

Coppola A, Cimino E, Conca P, De Simone C, Tufano A, Tarantino G, Cerbone A M, Minno G

机构信息

Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine, 'Federico II' University, Naples, Italy.

出版信息

Haemophilia. 2006 Jan;12(1):90-4. doi: 10.1111/j.1365-2516.2006.01184.x.

DOI:10.1111/j.1365-2516.2006.01184.x
PMID:16409182
Abstract

Prophylaxis with von Willebrand factor (VWF)-containing concentrates is considered to be a potential approach for patients with von Willebrand disease (VWD) and severe bleeding tendency. We report the case of a 57-year-old man with type 3 VWD and a history of recurrent melaena. Bleeding frequency and severity had progressively increased and the patient showed chronic anaemia and persistent haemoglobin in the stools. Endoscopic examinations revealed multiple vascular mucosal abnormalities (MVA) of the stomach and large bowel. Photocoagulation of some actively bleeding lesions and octreotide did not significantly affect his clinical conditions: six red cell transfusions and >400 000 IU of intermediate-purity factor VIII (FVIII) concentrate (Haemate P) on-demand were needed during 2002. Prophylaxis with Haemate P 40 IU kg(-1) (102 IU kg(-1) VWF:RCo) thrice weekly was associated with improvement of his mean haemoglobin levels, cessation of clear-cut melaena and red cell transfusions and reduction of total Haemate P requirements (-20% over 2003-04). Prophylaxis with Haemate P is still ongoing without any adverse event over a 30-month period. Clinical course and pharmacokinetic evaluations led to administer Haemate P each 72-96 h. Possible vascular complications were excluded by a careful clinical follow up, as the patient suffered from arterial hypertension and diabetes mellitus; thrombophilic abnormalities were previously excluded and no signs of abnormal coagulation activation or FVIII:C levels >150% were detected thereafter. Long-term prophylaxis with Haemate P has been shown to be safe, effective (also in terms of quality of life) and cost saving in this patient with severe gastrointestinal bleeding due to MVA and VWD.

摘要

对于患有血管性血友病(VWD)且有严重出血倾向的患者,使用含血管性血友病因子(VWF)的浓缩物进行预防被认为是一种潜在的方法。我们报告了一例57岁的3型VWD男性患者,有反复黑便病史。出血频率和严重程度逐渐增加,患者出现慢性贫血且粪便中持续有血红蛋白。内镜检查发现胃和大肠有多处血管黏膜异常(MVA)。对一些活动性出血病变进行光凝和使用奥曲肽对其临床状况没有显著影响:2002年期间,患者按需输注了6次红细胞以及超过40万国际单位的中纯度因子VIII(FVIII)浓缩物(海莫莱士)。每周三次预防性使用40 IU/kg(102 IU/kg VWF:RCo)的海莫莱士与患者平均血红蛋白水平的改善、明显黑便和红细胞输注的停止以及海莫莱士总需求量的减少(2003 - 2004年期间减少20%)相关。在30个月的时间里,仍在继续使用海莫莱士进行预防,未出现任何不良事件。临床病程和药代动力学评估导致每72 - 96小时给予一次海莫莱士。由于患者患有动脉高血压和糖尿病,通过仔细的临床随访排除了可能的血管并发症;之前已排除血栓形成异常,此后未检测到异常凝血激活迹象或FVIII:C水平>150%。对于因MVA和VWD导致严重胃肠道出血的该患者,长期使用海莫莱士进行预防已被证明是安全、有效的(在生活质量方面也是如此)且节省成本。

相似文献

1
Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding.对一名患有3型血管性血友病且反复出现胃肠道出血的患者,使用中间纯度的凝血因子VIII浓缩物(海莫莱士)进行长期预防治疗。
Haemophilia. 2006 Jan;12(1):90-4. doi: 10.1111/j.1365-2516.2006.01184.x.
2
Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.VIII因子/血管性血友病因子浓缩物(海莫莱士)在预防血管性血友病患者手术或侵入性操作期间出血的疗效和安全性。
Haematologica. 2003 Nov;88(11):1279-83.
3
Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.凝血因子VIII/血管性血友病因子浓缩物(Haemate-P/Humate-P)治疗血管性血友病患者的疗效及安全性:瑞斯托菌素辅因子单位剂量研究
Thromb Haemost. 2002 Feb;87(2):224-30.
4
Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.对血管性血友病患者持续输注凝血因子 VIII - 血管性血友病因子(vWF)联合浓缩物(海莫莱士)的安全性和有效性。
Thromb Haemost. 1999 Feb;81(2):229-33.
5
Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.海莫莱士/人抗血友病因子用于治疗血管性血友病:使用考量与临床经验
Haemophilia. 2008 Nov;14 Suppl 5:39-46. doi: 10.1111/j.1365-2516.2008.01850.x.
6
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.静脉注射去氨加压素和因子VIII-血管性血友病因子浓缩物用于治疗和预防1型、2型和3型血管性血友病患者的出血。
Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399.
7
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.首款巴氏灭菌的血管性血友病因子/凝血因子VIII药用产品Haemate P/Humate -P的系统综述:历史与临床疗效
Eur J Haematol Suppl. 2008 May(70):3-35. doi: 10.1111/j.1600-0609.2008.01049.x.
8
Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.血管性血友病因子/凝血因子VIII浓缩物的比较分析与分类:对血管性血友病患者治疗的影响
Semin Thromb Hemost. 2006 Sep;32(6):626-35. doi: 10.1055/s-2006-949668.
9
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).使用中间纯度的凝血因子VIII-血管性血友病因子浓缩物(海莫莱士)对2型血管性血友病患者进行大手术时的出血预防。
Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30. doi: 10.1097/00001721-200406000-00006.
10
Prophylaxis in von Willebrand disease.血管性血友病的预防
Haemophilia. 2008 Nov;14 Suppl 5:47-53. doi: 10.1111/j.1365-2516.2008.01851.x.

引用本文的文献

1
Burden of Illness and Treatment Patterns Among Patients With von Willebrand Disease in US Clinical Practice.美国临床实践中血管性血友病患者的疾病负担和治疗模式。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231177023. doi: 10.1177/10760296231177023.
2
Cost-consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context.意大利背景下血管性血友病长期预防治疗的成本-后果分析
Clinicoecon Outcomes Res. 2014 Dec 17;7:17-25. doi: 10.2147/CEOR.S71892. eCollection 2015.